Mylan, Sandoz Infringed Teva's MS Drug Patents, Judge Finds

Law360, New York (June 25, 2012, 7:20 PM EDT) -- In a major win for Teva Pharmaceutical Industries Ltd., a judge has ruled that Mylan Pharmaceuticals Inc. and Sandoz Inc. infringed the Israeli drugmaker's patents for Copaxone in making generic versions of the multiple sclerosis drug.

U.S. District Judge Barbara S. Jones issued a terse order on Friday in New York finding that Mylan and Sandoz's abbreviated new drug applications for generic Copaxone infringe all the asserted claims of nine Teva patents covering the drugs.

The judge, who said her full opinion would be released after...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.